156 related articles for article (PubMed ID: 10429977)
21. Regional chemotherapy for advanced pancreatic carcinoma.
Bayar S; Unal E; Tez M; Kocaoglu H; Demirci S; Akgul H
Hepatogastroenterology; 2003; 50(50):550-2. PubMed ID: 12749270
[TBL] [Abstract][Full Text] [Related]
22. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Ebrahimi B; Tucker SL; Li D; Abbruzzese JL; Kurzrock R
Cancer; 2004 Dec; 101(12):2727-36. PubMed ID: 15526319
[TBL] [Abstract][Full Text] [Related]
23. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
25. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
26. Radiation therapy, bypass operation and celiac plexus block in patients with unresectable locally advanced pancreatic cancer.
Yamaguchi K; Kobayashi K; Ogura Y; Nakamura K; Nakano K; Mizumoto K; Tanaka M
Hepatogastroenterology; 2005; 52(65):1605-12. PubMed ID: 16201126
[TBL] [Abstract][Full Text] [Related]
27. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
28. Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma.
Han GH; Yin ZX; Meng XJ; He CY; Zhang HB; Sun AH; Wu KC; Ding J; Fan DM
Chin J Dig Dis; 2006; 7(1):45-8. PubMed ID: 16412037
[TBL] [Abstract][Full Text] [Related]
29. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
30. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
31. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract][Full Text] [Related]
33. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
34. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
35. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
36. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
37. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
38. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
39. [Arterial infusion chemotherapy combined with concurrent radiotherapy for local advanced pancreatic cancer].
Liu X; Chen J; Yao W
Zhonghua Zhong Liu Za Zhi; 1999 Sep; 21(5):369-70. PubMed ID: 11776577
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
